Sign In
Buy EYPT
$12.34
-0.190 (-1.52%)
At Close: Jun 03, 2026
EyePoint Pharmaceuticals Announces Closing of $115 Million Public Offering of Common Stock
12:29pm, Thursday, 04'th Feb 2021
WATERTOWN, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
04:01pm, Monday, 01'st Feb 2021
WATERTOWN, Mass., Feb. 01, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the
EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for the Treatment of Wet AMD
07:00am, Thursday, 28'th Jan 2021
WATERTOWN, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve th
EyePoint Pharmaceuticals Provides Business Update and Preliminary Fourth Quarter and Full-Year 2020 Net Product Revenues
04:01pm, Monday, 11'th Jan 2021
- IND filed in December 2020 for EYP-1901, a potential six-month sustained delivery intravitreal anti-VEGF treatment targeting wet age-related macular degeneration -
Week In Review: China Biopharma Starts 2021 With Over $1 Billion In Deals And IPOs
03:16pm, Sunday, 10'th Jan 2021
Gracell Biotech completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a deal worth
EyePoint Pharmaceuticals Announces $15.7 Million Equity Investment by Asia Partner Ocumension Therapeutics
07:00pm, Sunday, 03'rd Jan 2021
WATERTOWN, Mass., Jan. 03, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products,
EyePoint Pharmaceuticals Announces $16.5 Million Monetization of ILUVIEN® Royalty with SWK Holdings Corporation
07:00am, Friday, 18'th Dec 2020
WATERTOWN, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative therapeutics to help
EyePoint Pharmaceuticals Announces 1-for-10 Reverse Stock Split
09:20am, Tuesday, 08'th Dec 2020
WATERTOWN, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products,
- No unexpected safety findings during the course of the study -
Where Do Hedge Funds Stand On EyePoint Pharmaceuticals, Inc. (EYPT)?
09:13am, Wednesday, 25'th Nov 2020
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors
EyePoint Pharmaceuticals to Host Key Opinion Leader Virtual Roundtable on the Future of Drug Delivery for Wet AMD on December 4
07:00am, Thursday, 19'th Nov 2020
WATERTOWN, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products,
EyePoint Pharmaceuticals Announces Presentations at the Upcoming American Academy of Ophthalmology 2020 Virtual Annual Meeting
07:00am, Tuesday, 10'th Nov 2020
WATERTOWN, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products,
EyePoint Pharmaceuticals, Inc.'s (EYPT) CEO Nancy Lurker on Q3 2020 Results - Earnings Call Transcript
08:37am, Sunday, 08'th Nov 2020
EyePoint Pharmaceuticals, Inc.'s (EYPT) CEO Nancy Lurker on Q3 2020 Results - Earnings Call Transcript
EyePoint Pharmaceuticals Announces Third Quarter 2020 Financial Results Release Date and Conference Call Information
07:00am, Thursday, 29'th Oct 2020
WATERTOWN, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products,
